搜索
Aligos Therapeutics Inc
ALGS添加自选
5.450USD
-0.320-5.55%
收盘 07/01, 16:00（美东）报价延迟15分钟
33.73M总市值
亏损市盈率 TTM
关于 Aligos Therapeutics Inc 公司
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Aligos Therapeutics Inc简介
公司代码ALGS
公司名称Aligos Therapeutics Inc
上市日期Oct 16, 2020
CEOBlatt (Lawrence M)
员工数量70
证券类型Ordinary Share
年结日Oct 16
公司地址One Corporate Dr., 2Nd Floor
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编94080
电话18004666059
网址https://www.aligos.com/
公司代码ALGS
上市日期Oct 16, 2020
CEOBlatt (Lawrence M)
Aligos Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Lawrence M. Blatt, Ph.D.
Dr. Lawrence M. Blatt, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
88.42K
--
Dr. Julian A. Symons
Dr. Julian A. Symons
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
35.11K
+55.11%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
5.22K
+30.85%
Mr. James P. (Jim) Scopa, J.D.
Mr. James P. (Jim) Scopa, J.D.
Independent Director
Independent Director
--
--
Dr. K. Peter Hirth, Ph.D.
Dr. K. Peter Hirth, Ph.D.
Independent Director
Independent Director
--
--
Ms. Carole L. Nuechterlein, J.D.
Ms. Carole L. Nuechterlein, J.D.
Independent Director
Independent Director
--
--
Dr. Bridget A. Martell, M.D.
Dr. Bridget A. Martell, M.D.
Independent Director
Independent Director
--
--
Mr. Jordyn Tarazi
Mr. Jordyn Tarazi
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Dr. Heather Preston, M.D.
Dr. Heather Preston, M.D.
Independent Director
Independent Director
--
--
Ms. Margarita Chavez, J.D.
Ms. Margarita Chavez, J.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Lawrence M. Blatt, Ph.D.
Dr. Lawrence M. Blatt, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
88.42K
--
Dr. Julian A. Symons
Dr. Julian A. Symons
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
35.11K
+55.11%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
5.22K
+30.85%
Mr. James P. (Jim) Scopa, J.D.
Mr. James P. (Jim) Scopa, J.D.
Independent Director
Independent Director
--
--
Dr. K. Peter Hirth, Ph.D.
Dr. K. Peter Hirth, Ph.D.
Independent Director
Independent Director
--
--
Ms. Carole L. Nuechterlein, J.D.
Ms. Carole L. Nuechterlein, J.D.
Independent Director
Independent Director
--
--
常见问题
Aligos Therapeutics Inc的前五大股东是谁？
Aligos Therapeutics Inc 的前五大股东如下：Dr. Lawrence M. Blatt, Ph.D.
有多少机构持有Aligos Therapeutics Inc(ALGS)的股份？
截至2026Q1，共有108家机构持有Aligos Therapeutics Inc的股份，合计持有的股份价值约为2.82M，占公司总股份的52.29%。与2025Q4相比，机构持股有所增加，增幅为-1521590.00。